300142 Walvax Biotechnology
- 13.54
- -0.80-5.58%
Walvax Biotechnology News
Watson Biotech: Announcement on receiving the “Drug Clinical Trial Approval Notice” for adsorbed tetanus vaccine
Watson Biotech: Prompt Announcement for the Disclosure of the 2024 Third Quarter Report
Watson Biotech: Announcement on the calculation of credit impairment preparations and asset impairment preparations for the third quarter of 2024
Watson Biotech: Announcement on the subsidiary receiving the Oman Product Registration Certificate for the 13-valent pneumococcal polysaccharide conjugate vaccine
Watson Biotech: Announcement on the subsidiary receiving a license to market the bivalent HPV vaccine in Indonesia
Watson Biotech: Notice on Completing the Registration of Business Changes
Watson Biotech: Announcement on subsidiaries applying for comprehensive credit lines from banks
Watson Biotech: Announcement on the 2024 Semi-Annual Credit Impairment Preparation and Asset Impairment Preparation
Watson Biotech: Announcement on holding an online briefing on 2024 semi-annual results
Watson Biotech: 2024 Semi-Annual Report Disclosure Reminder
Watson Biotech: Summary table of non-operating capital expenditure and other related capital transactions for the 2024 semi-year
Walvax Biotechnology: Announcement Regarding the Completion of Business Registration Changes for the Wholly-Owned Subsidiary.
Walvax Biotechnology: Announcement Regarding the Election of Vice Chairman of the Board and Changes to Some Senior Management Personnel.
Walvax Biotechnology: Announcement Regarding the Completion of Business Registration Changes for the Wholly-Owned Subsidiary.
Walvax Biotechnology: Voluntary Information Disclosure Announcement about the Appointment of Certain Core Management Personnel.
Walvax Biotechnology: Peking Guofeng (Shanghai) Law Firm's Legal Opinion Regarding the First Extraordinary Shareholders' Meeting of the Company in 2024.
Walvax Biotechnology: Announcement of the resolution of the first extraordinary Shareholders' Meeting in 2024.
Walvax Biotechnology: Announcement Regarding the Change of the Purpose of Repurchased Shares and the Cancellation and Reduction of the Company's Registered Capital and Notification to Creditors.
Walvax Biotechnology: Announcement Regarding the Appointment of Company's CFO.
Walvax Biotechnology: Notice regarding the convening of the first extraordinary shareholders' meeting in 2024.
No Data
